IGF-1 LR3 (Long Arg3 Insulin-like Growth Factor-1) – Research Peptide 1MG

IGF-1 LR3 is a synthetic, long-acting analog of human Insulin-like Growth Factor-1 (IGF-1), a naturally occurring peptide hormone primarily produced in the liver in response to growth hormone (GH) stimulation. This modified version features an arginine substitution at position 3 (Arg3) and an additional 13-amino-acid extension at the N-terminus, resulting in an 83-amino-acid chain (compared to the native 70-amino-acid IGF-1). 

These structural changes significantly reduce binding affinity to IGF-binding proteins (IGFBPs), extend the peptide’s half-life to approximately 20–30 hours (versus minutes for native IGF-1), and enhance overall potency—often reported as roughly 3x that of standard IGF-1 in relevant research models. 

Key Research Areas and Observed Effects (Preclinical/In Vitro)

•  Muscle Growth & Hypertrophy: Promotes protein synthesis, satellite cell activation, hyperplasia (increase in muscle cell number), and mitogenesis. Studies highlight its role in skeletal muscle repair, recovery, and overall anabolic signaling. 

•  Fat Metabolism & Body Composition: Supports lipolysis (fat breakdown), improved insulin sensitivity in muscle tissue, and potential benefits for metabolic regulation and body recomposition in research settings. 

•  Tissue Repair & Regeneration: Enhances cellular proliferation, differentiation, and recovery processes across muscle, soft tissue, and other models. 

•  Additional Investigated Areas: Cellular growth signaling, anti-aging/cellular regeneration pathways, and neuroprotection/cognitive research. 

For Research Use Only (RUO)